The U.S. Food and Drug Administration (FDA) has approved Ebglyss™, a targeted IL-13 inhibitor, for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 years and older who weigh at least 88 pounds (40 kg). This approval is significant for patients whose eczema has not been well controlled by topical prescription therapies. Ebglyss™ works by inhibiting IL-13, a key cytokine involved in the inflammation process underlying atopic dermatitis. This provides a new option for patients seeking effective treatment for their condition.